Skip to content Skip to sidebar Skip to footer

Newsletter

Charlie Youlden

Charlie is an Associate Equity Research Analyst covering ASX small caps across technology, mining and industrials.

His investing journey began in 2020 with large-cap US technology stocks, before he went on to complete a Commerce degree in Finance and Marketing at UTS, the Wall Street Prep Financial Modelling course, and Columbia Business School’s Value Investing course.

Charlie’s goal is to make investing clear, digestible and genuinely useful for everyday retail investors, helping them make better decisions with more confidence.

749 articles published

Healthcare Stocks Technology

Why Investors Are Watching Nanosonics (ASX: NAN) After a Strong Earnings Surge

Is CORIS the Catalyst for Nanosonics’ (ASX: NAN) Next Phase of Expansion? Nanosonics (ASX: NAN) has caught the market’s attention, with its share price climbing 14 percent over the past week as excitement built ahead of its full-year results. The earnings release did not disappoint, giving investors fresh confidence in the company’s long-term growth story. At…

ByCharlie YouldenAugust 26, 20250Comments

Large Caps

Coles Jumps on Full-Year Results: What Investors Need to Know

Coles (ASX: COL): Stability Today, Efficiency Gains Tomorrow Coles Group (ASX: COL) opened the day up nearly 4 percent at $21 after releasing its full year results, and the reaction tells us something important about how investors see this company. In a market where volatility and uncertainty dominate the headlines, Coles is being treated as a…

ByCharlie YouldenAugust 26, 20250Comments

Mining Stocks Technology

Metallium (ASX:MTM): From 900% Growth to U.S. Policy Tailwinds – What’s Next?

Metallium (ASX: MTM): Chasing a Rare Earths Breakthrough Metallium Limited (ASX: MTM) sits at the center of one of the most pressing issues in global markets today. Rare earth elements are critical to everything from electric vehicles to defense systems, yet nearly 90 percent of processing remains concentrated in China. That control gives Beijing extraordinary pricing…

ByCharlie YouldenAugust 26, 20250Comments

Small Caps Stocks Tech Stocks Technology

CurveBeam AI Jumps 37%: Opportunity or Overreaction?

CurveBeam AI Surges 37% as Investor Optimism Builds CurveBeam AI (ASX: CVB) caught the market’s attention this week after its share price surged 37 percent in a single move. For a relatively small medical imaging and artificial intelligence company, that kind of rally does not happen without sparking questions. The immediate trigger was an Appendix…

ByCharlie YouldenAugust 21, 20250Comments

Blue Chip Stocks Technology

Inside NVIDIA’s Omniverse: Jensen Huang’s Vision for the Future of Robotics

NVIDIA’s $4 Trillion Question: Growth Story or Peak Hype? NVIDIA (NASDAQ: NVDA) has become one of the most extraordinary success stories in modern markets, climbing to a market value of more than 4 trillion dollars under the leadership of CEO Jensen Huang. Once known primarily for making chips that powered smooth graphics in video games,…

ByCharlie YouldenAugust 21, 20250Comments

Tech Stocks Technology

Objective’s Results Spark 19% Gains, but Is the Growth Just Beginning?

Objective Hits Record Highs as Recurring Revenue Powers Growth Objective Corporation (ASX:OCL) gave investors plenty to celebrate after its 2025 full-year results sent the stock up 19 percent to fresh all-time highs. For patient shareholders, the rally capped an impressive 80 percent return over the past year. The company has been steadily reshaping itself into…

ByCharlie YouldenAugust 21, 20250Comments

Tech Stocks Technology

Why Did Megaport Drop 18% After Strong Results?

Megaport’s Strong Results Met With a Sharp Sell-Off Megaport (ASX:MP1) caught investors off guard this reporting season. Despite delivering strong results, its share price slid 18 percent in a single session. For a company riding the artificial intelligence boom and positioning itself as a leader in Network as a Service, that kind of drop was…

ByCharlie YouldenAugust 21, 20250Comments

Healthcare Stocks

Is the Market Missing Telix’s Long-Term Potential after 63% Revenue Growth?

Telix Pharmaceuticals: Controversy, Growth, and the Road Ahead Every investor knows the uneasy feeling of watching a stock fall, not because of poor earnings, but because of controversy. That is the position Telix Pharmaceuticals (ASX: TLX) finds itself in today. After headlines about an FDA subpoena related to how it communicated drug progress to investors,…

ByCharlie YouldenAugust 21, 20250Comments

Healthcare Stocks

Argent BioPharma Jumps 86% After Bold AusCann Acquisition

Argent BioPharma Expands with AusCann Deal On August 19, Argent BioPharma (ASX: RGT) announced it was buying AusCann’s assets, which include the 100% ownership of the Neuvis drug delivery platform, 48% of CannPal Animal Therapeutics, and part of 20% of ECC Pharm. This deal gives Argent new technology, more research data, and access to the…

ByCharlie YouldenAugust 19, 20250Comments

Mining Stocks

Magnetite Mines Surges 181%: Is Ironback Hill the Next Rare Earth Breakthrough?

Rarely does a stock surge 181% overnight on the back of old drill samples. That’s exactly what happened when Magnetite Mines (ASX: MGT) jolted the ASX with news of rare earths mineralisation at its Ironback Hill Project in South Australia. For years, this ground was known mainly for iron ore. But by re-testing archived drilling…

ByCharlie YouldenAugust 19, 20250Comments